Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Managing mCRPC in daily practice: a pragmatic approach

17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress (ECC 2013)

Sorry, this item is currently unavailable.

Published: 10 Jan 2014

Views: 3182

Rating:

Save

Dr Alison Birtle - Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK

Interesting personal case of Alison Birtle: a 69-year old man who developed mCRPC in 2008 and is still alive in September 2013. The patient had a good clinical response to docetaxel, cabazitaxel and abiraterone given sequentially but PSA was never informative.

“The physicians should be aware that such cases may happen and that treatment in such cases should be guided by clinical response and/or radiological response”.

Content taken from a Sanofi sponsored satellite symposium at ESMO 2013 as part of the official programme.

Related Videos

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

More from ecancer